Compare Heron Therapeutics Inc (HRTX) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nokia Corp — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Nokia Corp trades at $10.38 (market cap $56.99B). The key difference: Nokia Corp is far larger — about 838× Heron Therapeutics Inc's market cap, and Nokia Corp pays a 1.61% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Nokia Corp for 66 Days on average.
| HRTX | NOK | |
|---|---|---|
Market Cap | $68.01M | $56.99B |
Volume | 1,891,941 | 69,968,204 |
Sector | Health | Technology |
52-Week High | $1.49 | $16.83 |
52-Week Low | $0.27 | $5.18 |
Typical Hold Time | 35 Days | 66 Days |
Enterprise Value | $174.75M | $55.01B |
Dividend Yield | — | 1.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Nokia (NOK) trades at $10.62, down 3.19% on the day, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89 billion with a net income margin of 3.47%. Recent news highlights a strategic partnership with Microsoft for AI-driven network automation and sovereign satellite network development with ICEYE, positioning Nokia for growth in AI and telecommunications infrastructure.
The outlook for Nokia is positive, supported by strong analyst consensus with a $17.50 price target and 61.5% buy ratings. Key opportunities include expanding AI and cloud orders, which grew 105% in Q2 2026. Risks involve competitive pressures in telecom equipment, reliance on global infrastructure spending, and volatility in net cash flow, which turned negative in 2025. Execution on partnerships and margin expansion are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
